Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of VGT-309 in Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Be willing and able to sign the informed consent and comply with study procedures.~2. Be between the ages of 18 and 85, inclusive.~3. Be male or female and meet the following conditions:~   1. Female participants must be of non-childbearing potential, or,~  2. If of childbearing potential be non-pregnant or non-lactating and agree to use highly effective contraception from screening through Day 30.~  3. Male participants, if not surgically sterilized, and if engaging in sexual intercourse with a female partner of childbearing potential, must be willing to use highly effective contraception from screening through 30 days post-dose and agree not to donate semen during this waiting period.~  4. Highly effective contraception involves the use of a condom for the male, plus one of the following for the female:~      * Oral, injectable, implantable, intravaginal, or transdermal hormonal contraceptives, or~     * Intrauterine device or intrauterine hormone-releasing system~     * NOTE: Participants who abstain from heterosexual intercourse as their usual and preferred lifestyle, will not be required to use contraception as described above.~   They are required to maintain abstinence from screening through Day 30.~4. Have a lung nodule or mass that might be considered primary lung cancer or lung metastases, whether or not it is biopsy-proven.~5. Be scheduled to undergo standard of care surgical resection for a lung nodule or mass with diagnostic and/or curative intent and meet all pre-operative surgical and anesthesia acceptance criteria.~6. Have acceptable kidney and liver functions at study entry as evidenced by:~   1. Alanine Aminotransferase/Aspartate Aminotransferase (ALT/AST) \< 1.5 times the upper limit of normal~  2. Serum creatinine \< 1.5 times the upper limit of normal~7. Have an Eastern Cooperative Oncology Group (ECOG) score of 0-2.~8. Meet all standard surgical and general anesthesia requirements.~9. Have not participated in a clinical trial within the last 30 days.~Exclusion Criteria:~1. They are not a candidate for standard of care surgery based on opinion of the surgeon, anesthesiologist, or other consulting physician.~2. They have a known allergy or reaction to indocyanine green (ICG), other radiographic contrast agent, or any component of VGT-309.~3. Have congenital long QT syndrome or QTcF \> 450ms (males) or \>470ms (females) by history or at Screening ECG.~4. They are prisoners, institutionalized individuals, or are unable to consent for themselves.~5. Have any other co-morbidity or habit that the Investigator believes will interfere with their ability to comply with and complete the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 0.32mg/kg VGT-309 (Type: EXPERIMENTAL): Single arm in an open label study

Based on this trial design, predict the completion outcome and termination type (if applicable).